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The announcement this spring
followed months of speculation:
Kim Nasmyth will assume the
Whitley Chair of Biochemistry at
the University of Oxford at the
start of 2006, taking over from Ed
Southern. Nasmyth is presently
Director of the Institute of
Molecular Pathology (IMP) in
Vienna and is well known for his
work on the yeast cell cycle and
chromosome segregation (for
more details see Curr. Biol. 8,
R257–R258). He has received
numerous scientific awards and is
a Fellow of the Royal Society and
a Member both of the Austrian
Academy of Sciences and of the
American Academy of Arts and
Sciences.
Graham Tebb: Since joining the
IMP you have received many
offers of positions but have
declined them all. What prompted
you to consider an approach at
the present time?
Kim Nasmyth: I’ve been Director
of the IMP since 1997. When I
took up the position I thought ten
years would be about the right
length of time to be in charge, for
the sake of the institute as well as
of myself. It is good that the
director has a large degree of
influence but for this reason it’s
important that the position rotates
fairly regularly. Not too frequently,
of course: it would have been
irresponsible of me to have left
earlier than now because of the
upheaval involved in selecting a
new Director. And my involvement
in the setting up of the Institute for
Molecular Biotechnology, (see
Curr. Biol. 13, R39–R42) gave me
another good reason to stay.
GT: But you feel that now is a
good time for you to move on?
KN: Yes. The ultimate reason for
moving is that it forces you to do
things differently. Transplanting
yourself into a new environment,
no matter how painful it is, helps
make new connections and thus
advances your research in an
unpredictable way. Beyond a
certain age it is not easy to obtain
good positions, at least in Europe.
I’ll be 53 when I move to Oxford
and should still have enough time
before I retire to do something
worthwhile. But I imagine that this
may be my final position.
GT: The approach from Oxford
came at the right time for you.
Was there anything special about
Oxford that encouraged you to go
there?
KN: Of course. Oxford is an
extremely prestigious university
and the biochemistry department
enjoys — deservedly — a very
high reputation. I was naturally
honoured to be offered the
position. And I was attracted by
the idea that I could continue to
run a lab: I still enjoy research
enormously and would not have
been keen on going somewhere
where I would have had to give
this up. I have been very
impressed with the department’s
approach in its negotiations with
me: the agreement to build a new
building was a welcome sign of
the willingness to make changes. 
GT: What are your plans for your
future research?
KN: It’s clear that most, if not all,
really innovative research is done
by younger people but many of us
‘oldies’ cling to the notion that we
can still make a contribution. I’m
under no illusions on this score
and recognize that my best
research has possibly already
been done. Nevertheless, I have a
fair amount of unfinished business
and would like to continue to work
on the issues we’ve been
addressing for the past few years.
Although I am not a biochemist by
training, my work has become
much more biochemical over the
past decade. Our studies of
chromosome separation are at the
stage where we have identified
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many of the key players and we
now need to look at the
biochemistry of the process to
understand the mechanisms
involved. A better understanding
of the biochemistry will also
provide insights into meiosis and
into how it fails, for example as
women age. We’re currently trying
to extend our findings in yeast to
mice and hope to generate
reagents that will give us a handle
on understanding reproductive
biology.
GT: The popular press paints a
fairly grim picture of research
funding in the UK.
KN: After a period of neglect [of
research funding], the UK seems
now to be moving in the right
direction and the situation has
definitely improved over the past
five years. However, the matter of
salary structures in universities
requires urgent attention. Without
this, good people will continue to
leave universities for better-paid
jobs elsewhere. There are two
fundamental problems:
universities often are or have been
reluctant to deviate from rigid
salary scales; and the required
money is quite simply not
available. There have been signs
of change on the former point and
it is now time to address the latter
problem. 
There are a number of other
changes that need to be made
soon. At present, a fair amount of
research funding is provided by
research grants. Unfortunately,
though, these are not associated
with proper overhead costs so it
doesn’t pay universities to
support staff active in research
because they end up costing the
universities more. Too much
money is still being made
available without peer review.
Research grants are generally
peer-reviewed so represent a
better means of supporting
infrastructure – but only if they
come with realistic overheads.
And scientists need to be
encouraged to apply for more
research grants: the US system of
offering people salaries for only
nine months of the year and
expecting them to cover the
remainder by means of grants has
much to recommend it.
It’s important to note that the UK
is currently grappling with many
issues that other European
countries have yet to face, such
as university funding. This point is
simply not on the political agenda
here [in Austria]. University
financing will ultimately mean
fees, no matter how unpopular
they will prove. The £3000
currently charged in the UK is way
too little but represents a step in
the right direction. Both Oxford
and Cambridge have already
announced that they plan to
expand their offers to people who
come from outside the EU and
thus pay more realistic fees. In the
US there has long been a healthy
competition between public and
private universities and this has
been good for the quality of
education on offer. Politicians in
[mainland] Europe remain
concerned with everybody’s
‘right’ to receive a university
education and are not really
thinking about how it can be
funded.
GT: You have spent most of your
working life in dedicated research
institutes but will now be moving
into a university environment.
What are your feelings on this?
KN: Very positive. Indeed, this is
one of the most attractive features
of the Oxford job. Research
institutes are by their very nature
very narrowly focussed and I was
eager to go to a broader
environment, somewhere where
interactions with people in
different fields would be easier, as
they tend to create novelty in
research. Also, I thought my
experience in research institutes
and industry would be of more
benefit to a university than to
another research institute. 
GT: The IMP is wholly owned by a
commercial company, Boehringer
Ingelheim. What have you learned
from working for a company?
KN: Boehringer Ingelheim has
shown a very enlightened attitude
to basic research. I am extremely
grateful for the support I have
received from the company, both
in my research and as director,
and hope to continue to work with
the company in future, if possible.
The experience I have gained of
how companies work on drug
discovery has added a unique
dimension to the job here. One of
my goals at the IMP was to
encourage BI to take risks in
research funding; the company’s
willingness to do so has been
largely instrumental in ensuring
that we have had the freedom to
pursue our research.
GT: Do you feel you have
accomplished all you hoped to at
the IMP? Do you have regrets at
leaving Austria?
KN: Max [Birnstiel, Nasmyth’s
predecessor as IMP Director] did
a magnificent job at the IMP. I feel
that I was able to build on the
foundations he had laid and move
both the scientific quality of the
institute and its international
reputation up a notch. I’m very
happy with the way the institute
has developed.
We have been very happy at the
IMP and in Vienna and it will
naturally be painful to leave.
GT: What do you hope to
accomplish at Oxford?
KN: In the IMP we have managed
to create an environment that is
attractive to young people. Oxford
is already attractive but it is not
yet in the same league as the MIT;
at the moment nowhere is. But
why not? It’s just a question of
expectations. I hope to be able to
help create a department where
high-quality candidates will apply
for positions and where they will
be happy in their work. The
department has an excellent staff
and I shall do all I can to ensure
that they are happy and have the
facilities they require to do good
science. A number of senior
people are due for retirement over
the next few years. The selection
of their replacements will be of
key importance... I hope my track
record will be helpful in hiring
good people: there is sufficient
flexibility in the UK system to
make this possible.
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